Completion of Construction for the biopharmaceutical API manufacturing facility in the Takasaki Plant

Completion of Construction for the biopharmaceutical API manufacturing facility in the Takasaki Plant

Tokyo, Japan, April 8, 2014 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo:4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") has completed the construction of the HA4 Plant (biopharmaceutical API manufacturing facility) at the Takasaki Plant in April 8, 2014.

The HA4 Plant has been installed as one of the largest bioreactors for recombinant animal cells (12,000 L bioreactor) in Japan, as well as a purification facility with a large column. By utilizing the manufacturing technology of biopharmaceutical products cultivated by the company, we will realize a larger scale and stable manufacture and continue to make efforts to provide the market with high-quality pharmaceutical products.

New plant overview

Plant Name: HA4 Plant

Scale: Built with reinforced concrete, four-storied, total floor area of approx. 3892 m2

Investment: Approx. 6 billion yen

Purpose: Manufacture of biopharmaceutical API

Schedule: Operations commence will be 1st half, 2016 (January to June)

Characteristics: (1) The facility complies with GMP in Japan, the US, and the EU.

(2) The facility is equipped with a 12,000 L bioreactor, which is one of the largest of its kind in Japan, as well as a large column compatible with this bioreactor.

 

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.